Category Archives: Diabetes

Suicide is a leading cause of deathamong young people ages 20 to 24 in the United States, and the risk is even higher in individuals with type 1 diabetes. In fact, up to 7% of deaths in individuals with type 1 diabetes are a result of suicide. However, current screening tools for depression and suicide often miss individuals at risk of suicide and the risk among the type 1 diabetes patient population is greatly underestimated.

The symposium will highlight the work of RESCUE and address solutions for two distinct uncertainties faced by health care providers in the management of people with type 1 diabetes at risk of suicide: how to identify those at risk and the best way to prevent and reduce that risk.

Discussion topics will include:

"Suicide and self-harm are an all-too-common reality for young adults with type 1 diabetes, but it doesn't have to be. With a multi-pronged approach to awareness, education, and identification, we have the opportunity to intervene on the link between suicide and diabetes," said Professor Katharine Barnard-Kelly, PhD., RESCUE Collaborative Community. "With this symposium, it is our hope that we can reach stakeholders with awareness and arm them with messages that can ultimately save a young person's life if adopted in clinical practice and through mental health screenings."

Professor Katharine Barnard-Kelly, PhD and the RESCUE team will present during the symposium, Suicide and Self-InjuryUnveiling and Addressing the Hidden Nightmare in Diabeteson Friday, June 3 from 4:156:15 p.m. CT.

For more information, please contact the ADA Scientific Sessions media team onsite at the Ernest N. Morial Convention Center from June 37 by phone at 504-670-4902, or by email at [emailprotected].

About the ADA's Scientific SessionsThe ADA's 82nd Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be a hybrid event held June 37, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA. Leading physicians, scientists, and health care professionals from around the world will unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. We are eager to get back to safely participating in person and networking with colleagues while hearing the latest scientific advances and groundbreaking research presentations. Learn more and register atscientificsessions.diabetes.organd join the Scientific Sessions conversation on social media using #ADA2022.

About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 81 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 133 million Americans living with diabetes or prediabetes. Diabetes has brought us together, what we do next will make us Connected for Life. To learn more or to get involved, visit us atdiabetes.orgor call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociacin Americana de la Diabetes),LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), andInstagram (@AmDiabetesAssn).

SOURCE American Diabetes Association

Read more here:
American Diabetes Association Symposium to Bring to Light the Impact of Suicide and Depression on Adolescents with Type 1 Diabetes - PR Newswire

DALLAS May 31, 2022 The rapid adoption of telemedicine and increased use of continuous glucose monitoring helped to attenuate the impacts of the COVID-19 pandemic on children with Type 1 diabetes, according to a new study from UTSouthwestern researchers.

Abha Choudhary, M.D.

The pandemic had profound effects on disease management when shutdowns occurred in 2020, creating barriers for those who lost jobs and insurance and aggravating existing health disparities. Several studies have shown that the pandemic worsened glucose control in patients with diabetes and made it more difficult to access care.

Our diabetes team implemented telemedicine visits within weeks of the shutdown, allowing us to provide care to our patients in an efficient and timely manner, said Abha Choudhary, M.D., Assistant Professor of Pediatrics at UTSouthwestern and a pediatric endocrinologist at Childrens Health. Our team was also able to utilize continuous glucose monitoring for a growing number of patients which may have helped to mitigate some of the challenges brought on by the pandemic.

For the study published in BMC Pediatrics, Dr. Choudhary and colleagues used data from Childrens Medical Center Dallas to determine how the management of patients with Type 1 diabetes was affected by the pandemic in a large urban setting. They analyzed patient characteristics including insurance status, race, ethnicity, gender, glucose control, office visits, and hospitalizations, and compared the use of continuous glucose monitoring in the year prior to the start of the pandemic to the first year of the pandemic.

The study found that while the number of office visits among patients decreased during the pandemic, there was no effect on disease management in this group both glucose control and hospitalization rates were unchanged.

However, the results highlighted existing disparities among patients in minority and low-income demographics. Both before and during the pandemic, Black and Hispanic patients and those without commercial insurance had worse glucose control and higher hospitalization rates than their white, non-Hispanic, insured counterparts.

While the use of continuous glucose monitoring was higher among insured patients overall, there was a dramatic increase in use by patients without commercial insurance during the pandemic. This is likely due to the increased availability of glucose monitoring systems offered to Medicaid recipients in Texas that took effect during the pandemic, Dr. Choudhary explained.

The researchers believe the increased use of continuous glucose monitoring along with the successful implementation of telemedicine greatly contributed to preventing worse outcomes in this patient population.

For all the progress we have made, significant disparities remain with regard to access to some of the tools we think made the biggest differences during the early months of the pandemic, said Dr. Choudhary. From broadband access to the hardware and software thats so central to diabetes care these days, weve only begun to scratch the surface when it comes to addressing disparities in technology and remote-patient monitoring.

UTSouthwestern is ranked among the top 25 hospitals in the nation for diabetes and endocrinology by U.S. News & World Report.

About UTSouthwestern Medical Center

UTSouthwestern, one of the nations premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 26 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,900 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in more than 80 specialtiesto more than 100,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 4 million outpatient visits a year.

Read more:
Telemedicine, continuous glucose monitoring mitigated effects of pandemic on children with diabetes - UT Southwestern

A commercial drivers license (CDL) is a drivers license necessary to operate trucks and drive interstate. Previously, people with diabetes may not have met the criteria to get a CDL. However, while a person needs to meet numerous health requirements, it is possible for those living with diabetes to become truck and bus drivers.

Prior to 2003, there was a ban on trucking for individuals with insulin-treated diabetes, both type 1 and type 2.

In 2003, the Federal Motor Carrier Safety Administration (FMCSA), the agency regulating the trucking industry in the United States, began a system known as the Diabetes Exemption Program. Through this lengthy process, a person with insulin-treated diabetes could obtain an exemption to operate large trucks.

However, in 2018, the FMCSA ended the program. Instead, a person living with diabetes can obtain a Medical Examiners Certificate (MEC), a standard certification other drivers need to provide to confirm they are physically able to operate a commercial vehicle.

An individuals treating clinician completes the assessment form attesting that they have a stable insulin regimen and properly controlled diabetes.

In this article, we discuss how a person with type 2 diabetes can pass their CDL, what it involves, and how long it is valid. We also suggest tips for driving with diabetes.

Following the new ruling by the FMCSA for people living with diabetes in 2018, a person with type 2 diabetes can obtain their CDL.

The new rule reflects modern diabetes management and means there is no longer a blanket exclusion against insulin use.

Previously, it was more difficult for people with insulin-treated diabetes to obtain their CDL. However, the new ruling supports that people with diabetes can safely operate commercial motor vehicles.

According to the new regulations, individuals with type 2 diabetes who do not require insulin only need to follow their state guidelines to obtain and keep a CDL.

If a person with type 2 diabetes requires insulin, they will now only need to obtain a MEC to confirm they have a stable insulin regimen and are able to manage their condition.

Under the new ruling, a listed certified medical examiner (CME) can grant a person with insulin-treated diabetes a MEC for up to 12 months.

To do so, the healthcare professional who manages and prescribes insulin for the person provides the assessment form to the CME. The CME will then determine if the person meets the FMCSAs qualification standards.

These standards include:

The assessment will also detail whether the person has recently experienced a severe hypoglycemic episode or any potential complications due to type 2 diabetes.

The FMCSA estimates that the annual cost to comply with this ruling is $332, which is significantly lower than the cost prior to the 2018 rule change.

The maximum period of medical certification under the new rule is 12 months. This new ruling is applicable in every state and U.S. territory.

To be eligible for the maximum 12 months, an individual needs to be able to provide sufficient evidence that they are able to manage their condition.

This includes being able to provide at least the preceding 3 months of blood glucose self-monitoring records. Without this, a CME may only be able to provide them a 3-month certificate to allow them to collect the necessary records.

Living with diabetes can affect a persons ability to drive, as they need to ensure their blood sugars are at suitable levels and may develop complications that may make it more difficult to drive.

Some tips for driving may include:

For individuals living with type 2 diabetes, it may be advisable to try the following:

Following the new ruling the FMCSA introduced in 2018, it is easier for people with type 2 diabetes to obtain a CDL. Individuals with insulin-treated diabetes need to obtain a MEC to operate commercial motor vehicles.

The FMCSA keeps a registry of CMEs. These healthcare professionals determine whether a driver meets the FMCSAs physical qualification standards to hold a CDL. This certification is valid for 12 months and enables a person to obtain a CDL.

Read the original here:
Can a person pass their CDL if they have type 2 diabetes? - Medical News Today

Users of insulin pumps may be used to a certain regimen associated with managing their diabetes. That can include carbohydrate counting, setting basal rates and more.

Beta Bionicshas set out to change that. With the Concord, Massachusetts-based companys iLet bionic pancreas, the user inputs just one number: their body weight.

The company designed the pocket-sized, wearable, investigational iLet device to autonomously dose insulin. Worn like an insulin pump, iLet users only enter body weight to initialize therapy without the need for insulin regimen parameters. The company designed the device to then automatically titrate and infuse insulin without requiring the counting of carbs, the settings of certain rates and factors and more.

Its very qualitative, not quantitative, Beta Bionics interim CEO and board member Martha Aronson toldDrug Delivery BusinessNews. This cognitive burden the amount of math you have to do every day if youre a person with type one diabetes is extraordinary. Our goal is to take away that cognitive burden for people who live with type one diabetes.

Get the full story at our sister site, Drug Delivery Business News.

Read more from the original source:
Beta Bionics looks to reduce 'cognitive burden' for those with diabetes with bionic pancreas - Mass Device

For the first time ever, WHO Member States have supported the creation of global targets for diabetes, as part of recommendations to strengthen and monitor diabetes responses within national noncommunicable disease (NCD) programmes.

The five new targets set the standard that, by 2030:

The aim is to reduce the risk of diabetes, and move towards a world where all people who are diagnosed with diabetes have access to equitable, comprehensive, affordable and quality treatment and care.

The recommendations and targets are a core part of work requested by Member States in a resolution at last years World Health Assembly (A74/A/CONF./5). This resolution also requested the WHO Secretariat to:

Far too many people with diabetes have either never been diagnosed or are not able to access the medicines and technologies that could improve their condition. said Dr Bente Mikkelsen, Director for Noncommunicable Diseases, WorldHealth Organization.

As one example, it is unacceptable that a century since the discovery of insulin, many people still cannot access this essential and life-saving medicine. The decision taken today, including the establishment of global coverage targets for diabetes, will empower Member States to accelerate action on diabetes, and support people living with diabetes, around the world.

A year of the Global Diabetes Compact

Much has happened since the launch of the Global Diabetes Compact at the 2021 Global Diabetes Summit, co-hosted by WHO and the Government of Canada to commemorate the 100th anniversary of the discovery of insulin. Six workstreams have beenestablished, covering vital areas such as access to essential medicines and health technologies, health promotion, and country work. Work has also been taken to implement the Global Diabetes Compact at Regional Office level.

WHO has secured the assistance of leading experts to advise on diabetes technical matters, through the establishment of a Technical Advisory Group on Diabetes (TAG-D). We are also learning from people with lived experience of diabetes, acknowledging thatthis principle will help ensure the Global Diabetes Compact focuses on areas where action is most needed.A global informal consultation and focus groups have been conducted with people with lived experiences of diabetes, yielding vital insightson several topics including diabetes care, education, mental health and stigma associated with diabetes.

In addition, two meetings of the recently formed Global Diabetes Compact Forum have been held, with more than 70 participating organizations from civil society, academic institutions, philanthropic foundations, and business associations. The Forum providesan opportunity for the exchange of information and ideas that could be organized collectively for greater impact.

Scaling up our impact in countries around the world

The establishment of the Global Diabetes Compact and its associated coordination activities have brought added impetus to diabetes efforts within ministries of health around the world. Across the three levels of WHO, teams have used the opportunity tosupport countries in their efforts, providing technical guidance and support advocacy.

Over the past few months, WHO has secured funding for a 3-year project on the prevention and control of NCDs in primary care by prioritizing people living with diabetes in Kyrgyzstan and Uzbekistan.

WHO has been working hard to integrate diabetes into primary care, using the WHO Package of Essential Noncommunicable disease interventions (PEN) toolkit and HEARTS technical package. Mali is one of seven countries in the African Region currently implementingWHO HEARTS, including training health-care workers on managing diabetes. In South-East Asia, WHOs technical guidance on diagnosis and management of type 2 diabetes (HEARTS-D), has been adapted into an online training module for stakeholdersresponsible for planning diabetes services.

Every year until 2031, the WHO Secretariat will also submit a report on the implementation of the recommendations to the Health Assembly through the Executive Board, on an annual basis and as a component on the report on NCDs.

Link:
First-ever global coverage targets for diabetes adopted at the 75th World Health Assembly - World Health Organization

According to theCDC1, in the last 20 years, the number of adults diagnosed with diabetes has more than doubled as the American population has aged and become more overweight or obese. In addition, one study2 concluded that 3 out of 10 adults, or about 8 million people, have diabetes but aren't aware of it.

RBGM is an easy way for physicians to monitor patients that may be at risk for diabetes or patients with diabetes by simply providing a device they can take home. The iGlucose from Smart Meter utilizes the 4/5G AT&T IoT fast and secure network so patients and providers can track blood glucose levels in real time. This allows the provider to make an immediate diagnosis and implement a care program to improve outcomes.

A great example of the impact a remote blood glucose monitoring program can have on outcomes was seen at the Leon Medical Centers in South Florida. In 2021, Working with the Rimidi RPM platform, Leon patients who were considered high-risk with A1c levels above 9% were given an iGlucose and instructed by their doctor how often to take their blood-glucose reading. Of the approximately 225 high-risk patients who were enrolled in the program, 84% of those patients saw a reduction in their A1Cs below 9%, a key indicator of better diabetes control.

"In recent years, it's been proven that digitally connecting patients to their doctors between visits improves care and outcomes," said Casey Pittock, CEO, Smart Meter. "The conclusions of the program for Leon Medical Centers' patients are another example of how powerful RBGM can be. By providing these patients with a cellular-enabled iGlucose that transmits results immediately, it eliminated many barriers to reliable data that are seen with Bluetooth devices."

While remote patient monitoring has become more popular in recent years, education about its benefits is still needed. In fact, 45% of respondents in a Smart Meter study3 have never heard of RPM. Those who have heard of RPM programs overall feel it would help them increase their testing frequency.

About Smart Meter, LLC

Now working with more than 300 RPM distribution partners, who serve more than 120,000 patients, Smart Meter is the leading supplier of cellular-enabled virtual care technologies that include the iGlucose, iBloodPressure, iPulseOx, iScale, and SmartRPMcloud platform, as well as data, and services. Smart Meter's remote patient monitoring solutions are recognized as the standard for the RPM industry and are regarded for their high patient retention and satisfaction. The unique combination of reliable health data, patient-friendly devices, and platform integrations enable and enhance RPM, CCM, Employee Wellness, Population Health, and Telehealth programs for. For more information, visitSmartMeterRPM.com

1 Diabetes Quick Facts | Basics | Diabetes | CDC

2Nearly 3 in 10 Americans With Diabetes Don't Know It: Study - Consumer Health News | HealthDay

3Smart-Meter-National-Diabetes-Month-Survey.pdf (smartmeterrpm.com)

Smart Meter, LLC Media Contact5501 W. Waters Ave., Suite 401 Keith TolbertTampa, FL 33602 [emailprotected]813-773-4080 336-509-8024

SOURCE Smart Meter, LLC

Link:
RPM Software Provider Helps a Clinic Reduce A1c Levels for 84% of Patients Enrolled in a Program that Used the Cellular-Enabled iGlucose for Remote...

Chances are you know someone with diabetes. "37.3 million Americans, or 11.3% of the population, had diabetes" in 2019, according to the American Diabetes Association and "Nearly 1.9 million Americans have type 1 diabetes, including about 244,000 children and adolescents." In addition, "Of the 37.3 million adults with diabetes, 28.7 million were diagnosed, and 8.5 million were undiagnosed." Often signs of diabetes are missed, but Dr. Bayo Curry-Winchell, Urgent Care Medical Director and Physician, Carbon Health, and Saint Mary's Hospital tells Eat This, Not That! Health, symptoms to watch out for and how to help prevent diabetes. Read onand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID.

Dr. Curry-Winchell explains, "Diabetes is associated with a variety of symptoms such as an increase in thirst, changes in vision, and fatigue which can make it difficult to consider you might have diabetes. My patients often report seeing the eye doctor or thinking they need to get their vision checked or often associate the fatigue with an inadequate amount of sleep."

"Because diabetes affects so many organs in the body, if left untreated, it can lead to serious complications such as permanent vision loss, heart disease, and long-term kidney disease," Dr. Curry-Winchell says.

According to the Mayo Clinic, "Long-term complications of diabetes develop gradually. The longer you have diabetes and the less controlled your blood sugar the higher the risk of complications. Eventually, diabetes complications may be disabling or even life-threatening. Possible complications include:

Dr. Curry-Winchell states, "All ages are at risk for diabetes. The disease can affect anyone and if left untreated or not controlled, can lead to serious complications that can affect your quality of life."

Dr. Curry-Winchell explains, "There are two types of diabetes and it's important to highlight that you can't prevent the onset of type 1 diabetes. Although scientists have discovered possible connections that may be the cause, research is ongoing to find the exact cause at this time. For type 2 diabetes, mild to moderate exercise such as taking a walk and lifting weights like traditional dumbbells a couple of days a week and eating a diet that is balanced but also sustainable can help prevent diabetes."6254a4d1642c605c54bf1cab17d50f1e

The Mayo Clinic states, "Type 1 diabetes can't be prevented. However, the same healthy lifestyle choices that help treat prediabetes, type 2 diabetes and gestational diabetes can also help prevent them:

"If you notice you are drinking more fluids and it's not associated with increased activity or exercise this could be a sign of diabetes," says Dr. Curry-Winchell.

Your body is responding to an increase in blood sugar (glucose) circulating in your bloodstream. To decrease the amount of glucose, your kidneys increase the amount of time you need to urinate which means more trips to the restroom and increased water intake as your body attempts to replenish itself."

According to Dr. Curry-Winchell, "Vision changes like blurry vision due to high levels of glucose causes blood vessels in your eye to increase in size (swell) and become friable causing leakage."

Dr. Curry-Winchell explains, "Although you would think the increase in glucose should lead to more energy, it's the exact opposite. The increased sugar is not being used, instead it's circulating in the blood therefore your organs like your brain are not able to use it."

Heather Newgen

See the article here:
Signs You Have Diabetes and Don't Know It Eat This Not That - Eat This, Not That

For Immediate Release: May 13, 2022

Today, the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies.

Given the challenges many patients experience in achieving their target blood sugar goals, todays approval of Mounjaro is an important advance in the treatment of type 2 diabetes, said Patrick Archdeacon, M.D., associate director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDAs Center for Drug Evaluation and Research.

Type 2 diabetes, the most common form of diabetes, is a chronic and progressive condition in which the body does not make or use insulin normally, leading to high levels of glucose (sugar) in the blood. More than 30 million Americans have type 2 diabetes. Despite the availability of many medications to treat diabetes, many patients do not achieve the recommended blood sugar goals.

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood sugar control. Mounjaro is a first-in-class medicine that activates both the GLP-1 and GIP receptors, which leads to improved blood sugar control. Mounjaro is administered by injection under the skin once weekly, with the dose adjusted as tolerated to meet blood sugar goals.

Three different doses of Mounjaro (5 milligrams, 10 milligrams and 15 milligrams) were evaluated in five clinical trials as either a stand-alone therapy or as an add-on to other diabetes medicines. The efficacy of Mounjaro was compared to placebo, a GLP-1 receptor agonist (semaglutide) and two long-acting insulin analogs.

On average, patients randomized to receive the maximum recommended dose of Mounjaro (15 milligrams) had lowering of their hemoglobin A1c (HbA1c) level (a measure of blood sugar control) by 1.6% more than placebo when used as stand-alone therapy, and 1.5% more than placebo when used in combination with a long-acting insulin. In trials comparing Mounjaro to other diabetes medications, patients who received the maximum recommended dose of Mounjaro had lowering of their HbA1c by 0.5% more than semaglutide, 0.9% more than insulin degludec and 1.0% more than insulin glargine.

Obesity was common among study participants, with an average body mass index of 32 to 34 kilograms/height in meters squared reported at the time of enrollment. Among patients randomized to the maximum recommended dose, the average weight loss with Mounjaro was 15 pounds more than placebo when neither were used with insulin and 23 pounds more than placebo when both were used with insulin. The average weight loss with the maximum recommended dose of Mounjaro was 12 pounds more than semaglutide, 29 pounds more than insulin degludec and 27 pounds more than insulin glargine. Those patients receiving insulin without Mounjaro tended to gain weight during the study.

Mounjaro can cause nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort and abdominal pain.

Mounjaro causes thyroid C-cell tumors in rats. It is unknown whether Mounjaro causes such tumors, including medullary thyroid cancer, in humans. Mounjaro should not be used in patients with a personal or family history of medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2.

Mounjaro has not been studied in patients with a history of pancreas inflammation (pancreatitis), and it is not indicated for use in patients with type 1 diabetes.

Mounjaro received priority review designation for this indication. A priority review designation directs overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions.

The FDA granted the approval of Mounjaro to Eli Lilly and Co.

###

Boilerplate

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nations food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

See the original post:
FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes | FDA - FDA.gov

Participate virtually or join in-person to try to cross the University Street Bridge before it raises at 8:50 a.m.

SEATTLE It's back! The 40th Annual Nordstrom Beat the Bridge to Beat Diabetes benefiting JDRF returns this year with in-person and virtual participation opportunities.

On Saturday, May 14, lace up your sneakers and head to Husky Stadium for the 8K run and wheelchair race, 3-mile walk, 1-mile fun run, or the Diaper Derby for toddlers. KING 5's Steve Bunin will emcee the festivities. All funds raised support Type 1 diabetes (T1D) research. Since the first Beat the Bridge race in 1983, Nordstrom has partnered with JDRF to raise funds to cure, prevent and better treat T1D.

The event is called Beat the Bridge because the course travels over Seattles University Bridge, which is raised during the race. Participants try to cross the bridge before it is raised. Those who don't beat the bridge have to wait, with a live band and entertainment (it's a lively wait!), for the bridge to come back down. After a few minutes, the bridge lowers and everyone can finish the race.

When you support Beat the Bridge, you join more than 900,000 people including 2022 ambassadors Eli and Sophie who come together to raise funds to change the future for the millions of people with type 1 diabetes. KING 5 is proud to support Beat the Bridge.

Register today at beatthebridge.org or sign up onsite starting at 6:45 a.m. Check out the list of FAQs on their website to answer all of your questions before hitting the road.

Event Schedule for May 14, 2022:

6:45 a.m. - registration opens in the west concourse of Husky Stadium.

7:30 a.m. - Montlake Boulevard closes to ALL vehicle traffic

7:45 a.m. - 3-Mile Walk

8:15 a.m. - 1-Mile Fun Run

8:28 a.m. - Start of Wheelchair Race

8:30 a.m. - Start of 8K Race

8:50 a.m. - University Bridge goes up (approximate timethe bridge will go up 20 minutes after the last runner crosses start line)

9:00 a.m. - Fun on the field of the Husky Stadium

9:30 a.m. - Awards Ceremony

9:50 a.m. - Diaper Derby

Read the original post:
Join the 40th Nordstrom Beat the Bridge to Beat Diabetes - KING5.com

A diabetic woman quit her job after her manager allegedly not only sifted through her personal belongings without permission, but also accused her of doing drugs.

The woman, Abby Gebo, posted a video on TikTok in mid-April describing the encounter with management at her former unspecified workplace. The video has been seen about 83,000 times.

She said the manager allegedly "almost called the cops" on her, even announcing to another employee to prepare to make a call. Gebo, who according to the post may be a waitress, said the manager found her insulin in a backpack but did not originally know to who it belonged.

The manager reportedly said he "expected better" from her, inquiring whether she was holding on to the syringe for someone else. He also said he didn't know she was doing "drugs," again mentioning the syringe.

Perplexed, she told him she had diabetes and that he already knew that.

"My niece is a diabetic and she does not use syringes," the manager reportedly said. "I know that they use pumps."

She explained "that some people can't afford pumps" so they use vials and syringes, at which point he allegedly told her to "prove it." So, she showed him the vial.

"You're lucky," he said. "I'm watching you. ... I'm just making sure none of my staff does drugs."

That was the point when Gebo told him she quit. In other videos she talks about being a diabetic and being an advocate for others, so they "have access to specialized treatment and to know they are not alone."

Users were furious that her manager looked through her personal property in the first place. One user with type I diabetes said she would be "livid" if this situation happened to her.

"I would've gotten HR involved," one user said. "It's illegal to search your personal stuff."

"Under the Americans With Disabilities Act (ADA) they can't legally ask you so they are breaking the law when they ask you that," another said.

The ADA prohibits employers from discriminating against individuals with disabilities, of which diabetes is considered under the law. In 2013, when the United States had about 18 million citizens with diabetes, the U.S. Equal Employment Opportunity Commission stated that employers "may not ask questions about an applicant's medical condition or require an applicant to have a medical examination before it makes a conditional job offer."

That includes asking employees about being diagnosed with diabetes, or whether they use insulin, at a job interview. And even if an employee makes it known to an employer that he or she has diabetes, an employer "generally may not ask an applicant who has voluntarily disclosed that she has diabetes any questions about her diabetes, its treatment or its prognosis."

Questions could only be asked in that instance if an employee required a specific accommodation. Also, while employers can ask employees with diabetes if they have "a reasonable belief" that a job cannot be performed safely, that didn't seem to be the case as presented in the TikTok video.

Today, the Centers For Disease Control and Prevention estimate that about 37.3 million Americansor about 1 in 10have diabetes, including about one in five who have diabetes but have never been diagnosed.

Last year was the 100th anniversary of the discovery of insulin.

Gebo's profile also says she is "diabulimia recovery." The nonprofit National Eating Disorders Association (NEDA) calls it a "media-coined term" for an eating disorder in people with diabetes, usually type I diabetes. Such individuals purposefully restrict insulin so they can lose weight.

Some in the medical profession refer to it as ED-DMT1, Eating Disorder-Diabetes Mellitus Type 1, which refers more broadly to any eating disorder in those who have diabetes. ED-DMT1 is perceived as a result of focusing on food, labels, metabolic disruptions, and numbers like weight and blood glucose levels.

"A person may develop diabulimia or ED-DMT1 at any age and at any point after their diabetes diagnosis," the NEDA says. "Sometimes it begins with body image issues or a desire to lose weight, and sometimes it begins as diabetes burnout. Regardless of how it begins, treatment can be challenging as individuals with type 1 diabetes tend to show higher dropout rates and poorer treatment outcomes than other patients. Treatment regimens must address both the diabetes and eating disorder aspects of the disorder."

In March the U.S. House passed the Affordable Insulin Now Act, which would cap insulin at $35 and reduce out-of-pocket costs. Earlier this year, California Governor Gavin Newsom said he wanted the state to produce its own insulin.

Newsweek reached out to Gebo for comment.

Read the original post:
Woman Alleges Boss Threatened to Call Cops Over Her Diabetes Supplies - Newsweek